1-6 of 6
Tadeusz Robak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

Clinical Trials & Observations
Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak
Journal: Blood Advances
Blood Adv (2024) 8 (17): 4539–4548.
https://doi.org/10.1182/bloodadvances.2023012424
Published: 2024
Includes: Supplemental data
Journal Articles

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Clinical Trials & Observations
Pierre Fenaux, Marco Gobbi, Patricia L. Kropf, Jean-Pierre J. Issa, Gail J. Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop Kantarjian, Jan Novak, Wieslaw. W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph Brandwein, Liana Gercheva-Kyuchukova, Judit Demeter, Elizabeth Griffiths, Karen Yee, Konstanze Döhner, Yong Hao, Harold Keer, Mohammad Azab, Hartmut Döhner
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5027–5037.
https://doi.org/10.1182/bloodadvances.2023010179
Published: 2023
Includes: Supplemental data
Journal Articles

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Clinical Trials & Observations
Alessandro Broccoli, Lisa Argnani, Matthew Cross, Agnieszka Janus, Elsa Maitre, Xavier Troussard, Tadeusz Robak, Claire Dearden, Monica Else, Daniel Catovsky, Pier Luigi Zinzani
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4224–4227.
https://doi.org/10.1182/bloodadvances.2022007854
Published: 2022
Includes: Supplemental data
Journal Articles

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Claire Dearden, Sebastian Grosicki, Helen McCarthy, Jian-Yong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szoke, Thomas J. Kipps, Paolo Ghia
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3440–3450.
https://doi.org/10.1182/bloodadvances.2021006434
Published: 2022
Includes: Supplemental data
Journal Articles

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Clinical Trials & Observations
Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Nichola Cooper, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, James B. Bussel, Stephen Jolles
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4136–4146.
https://doi.org/10.1182/bloodadvances.2020002003
Published: 2020
Includes: Supplemental data
Journal Articles

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Clinical Trials & Observations
Steven E. Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard R. Furman, Jan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James, Susan M. O’Brien
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1799–1807.
https://doi.org/10.1182/bloodadvances.2018028761
Published: 2019
Includes: Supplemental data